Mitosol

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerPancreatic CancerColorectal CancerMetastatic Colorectal CancerBladder CancerNasopharyngeal CarcinomaAdenocarcinomaUrothelial CarcinomaUrinary Bladder CancerPhase IIColorectal NeoplasmColorectal CarcinomaChronic Renal Failure SyndromeMesotheliomaMyopiaOpen-Angle GlaucomaLung NeoplasmUrinary Bladder CarcinomaLocally Advanced Colon CancerTransitional Cell CarcinomaBladder Urothelial CarcinomaSclerosing CholangitisMetastatic Malignant NeoplasmClinical Stage IV Gastric Cancer AJCC V8Bladder TumorPterygiumKeratoconusMuscle-Invasive Bladder CarcinomaUrethral StricturePseudomyxoma PeritoneiCorneal DiseaseAnal CarcinomaAnus CancerAppendix Cancer

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

Mitosol

UUroGen Pharma Ltd.

Approved

382

Spravato

WWim Janssens

Preclinical

23

Feraheme

AAzurity Pharmaceuticals

Preclinical

14

Chantix

PPrism Pharmaceuticals

Preclinical

15

Nubain

AAultman Health Foundation

Preclinical

16

Rilvegostomig

AstraZeneca

Preclinical

17

Systemic Therapy

Bristol-Myers Squibb

Preclinical

18

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

19

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Preclinical

110

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Bladder Cancer8 trials

Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

Unknown status·UUniversity of Sydney·Phase 3·NCT02948543·501 enrolled

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Completed·MMayo Clinic·Phase 2·NCT03617913·2 enrolled

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04216290·95 enrolled

Show 5 more trials

Sequential Combination Therapy in Bladder Cancer

Unknown status·AAzienda Ospedaliera "Sant'Andrea"·Phase 4·NCT03790384·140 enrolled

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Active, not recruiting·NNottingham University Hospitals NHS Trust·Phase 3·NCT06462001·500 enrolled

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Completed·Radiation Therapy Oncology Group·Phase 2·NCT00981656·37 enrolled

POLO-Trial. Precise Neoadjuvant Chemoresection of Low-grade NMIBC Guided by Drug Sceens in Patient-derived Or-ganoids. An Open-label, Phase II Trial.

Not yet recruiting·UUniversity of Bern·Phase 2·NCT06227065·28 enrolled

Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids. A Single Center, Open-label, Phase II Trial With a Feasibility Endpoint. (GAIN-INST-TRIAL)

Active, not recruiting·RRoland Seiler-Blarer·Phase 2·NCT05024734·31 enrolled

Hepatocellular Carcinoma3 trials

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·SSecond Military Medical University·Phase 1/2·NCT02638857·60 enrolled

The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma

Withdrawn·SSeoul National University Hospital·Phase 2·NCT01953406

Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

Terminated·SSeoul National University Hospital·Phase 2·NCT01171482·5 enrolled

Liver Cancer2 trials

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003907·50 enrolled

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01004978·235 enrolled

Muscle-Invasive Bladder Carcinoma2 trials

A Pilot Study of Bladder Preservation or Cystectomy for Muscle-invasive Bladder Cancer Guided by Multi-omics: the B-PRECISE Study

Active, not recruiting·DDana-Farber Cancer Institute·Phase 1·NCT07821177·20 enrolled

Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Pilot Feasibility Trial

Recruiting·UUniversity of Washington·Preclinical·NCT07579195·12 enrolled

Esophageal Cancer1 trial

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02891447·24 enrolled

22 more indications

Fluorouracil1 trial

A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Terminated·—·Phase 1/2·NCT01671488·11 enrolled

Solid Tumors1 trial

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01017640·20 enrolled

Intensity-modulated Radiotherapy1 trial

Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal

Terminated·—·Phase 2·NCT01843452·8 enrolled

Phase II1 trial

Phase II Trial of Lung Chemoemobolization

Recruiting·—·Phase 2·NCT05672108·30 enrolled

Lung Cancer1 trial

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Completed·AAktion Bronchialkarzinom e.V.·Phase 3·NCT00148395·280 enrolled

Colorectal Carcinoma1 trial

Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.

Unknown status·Mario Negri Institute for Pharmacological Research·N/A·NCT03914820·330 enrolled

Locally Advanced Colon Cancer1 trial

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not yet recruiting·MMaimónides Biomedical Research Institute of Córdoba·Phase 3·NCT06783491·1,083 enrolled

Glaucoma1 trial

Lucentis Versus Mitomycin C During Glaucoma Surgery

Completed·WWills Eye·Phase 2/3·NCT00626782·24 enrolled

Colorectal Cancer1 trial

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04845490·201 enrolled

Efficacy and Safety1 trial

Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.

Completed·MMedical University of Lublin·Phase 1·NCT03766425·64 enrolled

LAM1 trial

Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy

Completed·FFederal University of São Paulo·N/A·NCT00654888·28 enrolled

Muscle Invasive Bladder Urothelial Carcinoma1 trial

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

Recruiting·NNRG Oncology·Phase 3·NCT07097142·486 enrolled

Anal Basaloid Carcinoma1 trial

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT04166318·252 enrolled

Non-Muscle Invasive Bladder Urothelial Carcinoma1 trial

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06770582·160 enrolled

Non-Muscle Invasive Bladder Carcinoma1 trial

MC240502: Cancer CARE (Connected Access and Remote Expertise) Beyond Walls In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes

Recruiting·MMayo Clinic·Preclinical·NCT06704191·40 enrolled

AIDS-Related Anal Carcinoma1 trial

Risk-Adapted Therapy for HIV-Associated Anal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04929028·40 enrolled

Appendix Cancer1 trial

Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial

Recruiting·CCity of Hope Medical Center·Phase 3·NCT07271355·129 enrolled

Gastric Cancer1 trial

A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases

Recruiting·UUniversity of Chicago·Phase 2·NCT04107077·21 enrolled

Bladder Urothelial Carcinoma1 trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03775265·475 enrolled

Clinical Stage IV Gastric Cancer AJCC v81 trial

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

Recruiting·CCity of Hope Medical Center·Phase 1·NCT04329494·49 enrolled

Anal Squamous Cell Carcinoma, Limited-stage1 trial

A Multicenter, Phase III, Randomized Controlled Clinical Trial of Sintilimab Versus Mitomycin in Combination With Capecitabine and Intensity-Modulated Radiotherapy in the Treatment of Limited-stage Anal Squamous Cell Carcinoma

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 3·NCT07692152·350 enrolled

Unspecified1 trial

Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy

Unknown status·AAsmaa Ahmed Ali Youssif·Phase 1·NCT04493073·100 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News